- Alexion Pharmaceuticals (NASDAQ:ALXN -0.2%) has agreed to co-develop CP010, a C6 complement inhibitor for the potential treatment of neurodegenerative disorders, with privately held Amsterdam-based Complement Pharma.
- Under the terms of the partnership, Alexion will provide Complement with up to €14M in milestone payments through Phase 1b development. Alexion has the option to acquire Complement during the term of the agreement.
Alexion teams up with Complement Pharma to develop C6 complement inhibitor
Recommended For You
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ALXN | - | - |
Alexion Pharmaceuticals, Inc. |